Literature DB >> 9292518

Influence of interleukin-3 and other growth factors on alpha4beta1 integrin-mediated adhesion and migration of human hematopoietic progenitor cells.

K P Schofield1, G Rushton, M J Humphries, T M Dexter, J T Gallagher.   

Abstract

The mechanisms by which hematopoietic progenitor cells are normally anchored in stromal niches and yet can be mobilized by specific growth factors are poorly understood. It is likely, however, that integrins and their extracellular matrix (ECM) ligands play a key role in this process, and recent evidence suggests that integrin function is modulated by signals originating from activated growth factor receptors. We have now examined this further by studying the role of growth factors on alpha4beta1 integrin-mediated adhesion of human CD34+ hematopoietic progenitor cells to specific recombinant fibronectin fragments coated onto tissue culture dishes. Cells were prepared from cord blood and peripheral blood harvests. During a 30-minute adhesion assay a mean of 74% of CD34 cells attached to the so-called H120 fragment of fibronectin, which contains the strongest alpha4beta1 integrin-binding sequence. The level of cell adhesion was significantly reduced by low concentrations of interleukin-3 (IL-3) (2.5 to 10 ng/mL), whereas stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF) at these concentrations did not affect adherence of the cells. Migratory behavior of CD34 cells was examined using fibronectin fragments adsorbed onto a Transwell filter. The H120 fragment supported much higher levels of cell migration than the H0 fragment of fibronectin, which contains a weak alpha4beta1 integrin binding sequence. Over a 16-hour assay, migration of peripheral blood progenitor cells was increased slightly by SCF and by G-CSF. However, a marked stimulation was observed with IL-3, which significantly increased migration. Similar effects were noted with cord blood cells, although a small proportion of cells were able to migrate in the absence of growth factors. These results indicate that there is a highly selective and functional link between the alpha4beta1 integrin and IL-3/IL-3-receptor that could affect the position of stem and progenitor cells in the marrow stroma and influence their growth and development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9292518

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Surface-immobilization of adhesion peptides on substrate for ex vivo expansion of cryopreserved umbilical cord blood CD34+ cells.

Authors:  Xue-Song Jiang; Chou Chai; Yue Zhang; Ren-Xi Zhuo; Hai-Quan Mao; Kam W Leong
Journal:  Biomaterials       Date:  2006-01-10       Impact factor: 12.479

Review 2.  Current Understanding of the Pathways Involved in Adult Stem and Progenitor Cell Migration for Tissue Homeostasis and Repair.

Authors:  Polina Goichberg
Journal:  Stem Cell Rev Rep       Date:  2016-08       Impact factor: 5.739

3.  Covalent immobilization of stem cell factor and stromal derived factor 1α for in vitro culture of hematopoietic progenitor cells.

Authors:  Maude L Cuchiara; Kelsey L Horter; Omar A Banda; Jennifer L West
Journal:  Acta Biomater       Date:  2013-08-17       Impact factor: 8.947

4.  Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor.

Authors:  M R Young; K Kolesiak; M A Wright; D I Gabrilovich
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

5.  Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing.

Authors:  Linda M Scott; Gregory V Priestley; Thalia Papayannopoulou
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

Review 6.  Mechanisms of tumor growth and metastasis in head and neck squamous cell carcinoma.

Authors:  Jarrett E Walsh; Deanne M R Lathers; Angela C Chi; M Boyd Gillespie; Terry A Day; M Rita I Young
Journal:  Curr Treat Options Oncol       Date:  2007-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.